{"schema_version":"1","generated_at":"2026-10-29T04:03:07.158Z","data_as_of":null,"url":"https://www.findmykol.com/kol/amer-assal","json_url":"https://www.findmykol.com/kol/amer-assal/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"amer-assal","name":"Amer Assal","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"New York","state":"NY","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1952577884","orcid":"0000-0003-4707-9265","openalex":"A5052100524"},"summary":"Amer Assal is an Oncology physician. OpenAlex indexes 102 publications with 2,299 citations (h-index 22).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":102,"cited_by_count":2299,"h_index":22,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":16,"program_years":{"first":2021,"last":null},"rows_total":25,"shown":3,"withheld":22,"rows":[{"payer":"SANOFI-AVENTIS U.S. LLC","program_year":2025,"amount_usd":4161,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1952577884"},{"payer":"Fresenius Kabi USA, LLC","program_year":2025,"amount_usd":137.58,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1952577884"},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2025,"amount_usd":135,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1952577884"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1952577884","source":"payments"},"prescribing":{"data_year":2024,"areas_total":3,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":50,"classes_total":2,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":32.6,"drugs":[{"name":"Jakafi","share_pct":60},{"name":"Tasigna","share_pct":40}],"max_beneficiaries":null},{"class":"Other protein kinase inhibitors","setting":"prescribed","share_pct":17.4,"drugs":[{"name":"Xospata","share_pct":100}],"max_beneficiaries":null}]},{"area":"Anti-infectives","share_pct":35.9,"classes_total":2,"classes":[{"class":"Cytomegalovirus DNA Terminase Complex Inhibitor","setting":"prescribed","share_pct":22.8,"drugs":[{"name":"Prevymis","share_pct":100}],"max_beneficiaries":null},{"class":"Azole Antifungal","setting":"prescribed","share_pct":13,"drugs":[{"name":"Posaconazole","share_pct":100}],"max_beneficiaries":null}]},{"area":"Dermatology","share_pct":14.1,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":14.1,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"mixed","data_year":2024,"office_pct":40.5,"facility_pct":59.5},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2025029584","status":"verified"},{"title":"RGI-2001 with CNI-Based Prophylaxis Demonstrates Better Acute Gvhd-Free Survival Following Myeloablative Allohct without Increased Relapse: Comparison of a Multi-Center Phase 2b Study with a Contemporaneous CIBMTR Cohort","year":2024,"journal":"Biology of Blood and Marrow Transplantation","source_url":"https://doi.org/10.1016/j.jtct.2023.12.058","status":"verified"},{"title":"Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis","year":2023,"journal":"Haematologica","source_url":"https://doi.org/10.3324/haematol.2022.281958","status":"verified"},{"title":"The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses","year":2023,"journal":"Frontiers in Immunology","source_url":"https://doi.org/10.3389/fimmu.2023.1212203","status":"verified"},{"title":"The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses","year":2023,"journal":"bioRxiv (Cold Spring Harbor Laboratory)","source_url":"https://doi.org/10.1101/2023.01.03.519511","status":"verified"}],"source":"works"},"contact":{"address_1":"171 FORT WASHINGTON AVE","city":"New York","state":"NY","zip":"100323733","phone":"212-305-5098","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1952577884","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":22,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2016-06-16","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}